Latest Market Strategy News

Critical Resources has launched a systematic field exploration program at the Corona Pegmatite Field, aiming to expand its lithium resource pipeline within the Mavis Lake Project in Ontario, Canada.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

Fortuna Metals has appointed mineral sands marketing veteran Ian Hind to lead its marketing strategy as it ramps up drilling at the Mkanda and Kampini rutile projects in Malawi, aiming to advance resource definition and commercial viability in 2026.

Magellan Financial Group is handing over management of its $5.3 billion global equities funds to Vinva, adopting a new systematic strategy and slashing fees to boost client value.

Gentrack Group trims its FY26 revenue outlook amid strategic investments and signals a $20 million on-market share buyback post-H1 results.

Pure Resources has partnered with Oak Ridge National Laboratory to develop a rare earth extraction process from its Garnet Hills garnet, aiming to add critical minerals value alongside its industrial minerals business.

Astron Limited has updated its Donald Rare Earth and Mineral Sands Project with a refreshed Bankable Feasibility Study showing a pre-tax NPV8 of AUD 759 million, strengthened Indigenous agreements, and a targeted Final Investment Decision in Q2 2026.

One Click Group delivered a remarkable 1000% increase in new users and a 64% reduction in acquisition costs in Q1 2026, setting the stage for strong revenue growth ahead of tax season.

Bannerman Energy has locked in a landmark US$321.5 million strategic investment from CNNC Overseas Limited, enabling debt-free construction of its Etango Uranium Project and setting the stage for a Final Investment Decision in H2 2026.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.